AmerisourceBergen is continuing its steady rise through the Fortune 500 rankings and is now holding steady at 12, just behind General Electric on the prestigious list, according to this year’s publication by Fortune.

AmerisourceBergen, the second biggest pharmaceutical distributor in the U.S., rose from 32nd to 28th in 2014, thanks in no small part to its 10-year distribution deal with Walgreens.  Its upward trajectory continued to 16th the following year, and now it sits comfortably at 12th.

Fortune ranks companies by their total fiscal year revenue and together they represent nearly two-thirds of the nation’s GDP with $12 trillion in revenues and $840 billion in profits.

In order for AmerisourceBergen to continue working its way up the list, it will have to deal with same issues affecting its main competitor, McKesson, in fifth. These include the deflation of generic drug prices and fewer expected launches of generic drugs that are likely to put pressure on the entire industry and its profits for this and future years.

AmerisourceBergen has already taken steps to counter the problem through strategic acquisitions to enter new markets. These include MWI Veterinary Supply which takes it into the animal health distribution market, World Courier which opens the door to clinical trial logistics, and PharMEDium which positions AmerisourceBergen in the compounding market.

The company could also see a windfall of new revenue over the next few years as its partner Walgreens absorbs over 4,500 pharmacists through the Rite Aid merger.

Read the complete company profile at Fortune here, and check out previous VISTA Today coverage of AmerisourceBergen here.